Evaluation of the diabetogenic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: a pilot study
| Autor: | Giovanni Damiani, Paul S. Yamauchi, Aleksandra Vojvodic, Zekayi Kutlubay, Laura Atzori, Mohamad Goldust, Georgi Tchernev, Torello Lotti, Andy Goren, Nematollah Ahangar Narenjbon, Leon H Kircik, Leo Čabrijan, Uwe Wollina, Jacek C Szepietowski, Sidharth Sonthalia, Elham Rezaee, Rosalynn R.Z. Conic, Carmen Cantisani, Burhan Engin, Steven Paul Nisticò, Enzo Errichetti, Philippe Bahadoran, Ghasem Rahmatpour Rokni, Tannaz Dehpouri, Vito Giuseppe Di Lernia |
|---|---|
| Přispěvatelé: | İÜC, Cerrahpaşa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
HbA1c Metabolic syndrome Methotrexate Psoriatic arthritis Dermatology Gastroenterology Article 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Internal medicine Psoriasis Diabetes mellitus medicine BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Dermatovenerologija lcsh:Dermatology Glycemic 030203 arthritis & rheumatology medicine.diagnostic_test business.industry lcsh:RL1-803 medicine.disease Obesity Erythrocyte sedimentation rate business BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Dermatovenerology medicine.drug |
| Zdroj: | Dermatology Reports, Vol 11, Iss 1 (2019) Dermatology Reports Volume 11 Issue 1 |
| ISSN: | 2036-7406 2036-7392 |
| Popis: | Sonthalia, Sidharth/0000-0001-7444-4956; Wollina, Uwe/0000-0001-5933-2913; Engin, Burhan/0000-0002-5140-1926 WOS:000486628700001 PubMed ID: 31210916 Methotrexate (MTX) is a systemic immunosuppressant drug used for the treatment of psoriasis and psoriatic arthritis. Previous studies demonstrated a potential association between psoriasis and diabetes mellitus, obesity, atherosclerosis, hypertension, eventuating into metabolic syndrome. This study aimed at exploring the glycemic effects of MTX in psoriatic arthritis (PsA) patients. In this prospective cross-sectional study, 27 patients with PsA were evaluated. The status of PsA and presence of accompanying metabolic syndrome was determined by standard criteria and indices. Blood indicators including HbA1c, erythrocyte sedimentation rate, fasting blood sugar, total cholesterol, high-density lipoprotein, triglycerides, and C-reactive protein were examined before and 12 weeks after MTX therapy. There were no significant changes between HbA1c levels before and after MTX therapy in both genders (men: P=0.131, women: P=0.803). In addition,HbA1c levels in PsA patients with metabolic syndrome were not different before and after treatment (P=0.250). Finally, HbA1c levels did not change in PsA patients without metabolic syndrome before and after therapy (P=0.506). MTX in PsA patients does not appear to have hyperglycaemic effects in the short-term and can be safely used in patients with metabolic syndrome and diabetes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|